Cost of AstraZeneca’s next-gen Dublin project may top €600m
Manufacturing facility likely to be much larger than initially planned
AstraZeneca’s new pharma manufacturing facility in Dublin is likely to be significantly larger than the company first planned and could now cost up to €600 million, the Business Post understands.
The Anglo-Swedish company announced in September last year that it would build a next-generation active pharmaceutical ingredient (API) manufacturing facility at its Alexion campus in Blanchardstown.
At the time it said the project, which will be AstraZeneca’s first manufacturing facility in Ireland, would cost over ...